Liver Cancer Trial, Recruiting NCT06191120 Sponsor: UMC Utrecht Condition: Liver Cancer
Back to Liver Cancer

Liver Cancer Trial, Recruiting

NCT06191120
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older.
  • People with liver metastases (cancer that has spread to the liver) who have been recommended for surgery to remove those metastases by a specialist medical team.
  • People who have given written consent to participate in the study.
  • People who have at least one liver metastasis measuring 1.5 cm or more in its longest dimension, as seen on a scan such as an MRI, CT, or ultrasound.
  • People with colorectal cancer (bowel cancer) who received treatment before being recommended for liver surgery — including those whose liver metastases were found at the same time as their original cancer diagnosis, those whose liver metastases appeared later, and those having a repeat liver surgery.
  • People who are also having other local treatments (such as radiofrequency ablation) for cancer in other parts of the body, as long as at least one liver metastasis of sufficient size is still planned to be surgically removed.
  • People receiving radiotherapy to the original tumour site before surgery (for example, in rectal cancer).

Who may not be able to join:

  • People who are pregnant.
  • People who are receiving pre-surgery chemotherapy that does not include a drug from the fluoropyrimidine group of medicines (confirm with trial site if unsure whether a specific chemotherapy regimen qualifies).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: M. G.E.H. Lam, UMC Utrecht

Phone: +31 088 75 56474

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
UMC Utrecht
Registry
ClinicalTrials.gov
Start date
5 August 2024
Est. completion
1 September 2026

Where this trial is recruiting

🇳🇱 Netherlands

Primary endpoints

Tumor-level CMS4 status as assessed by the current RNA-sequencing based CMS4 status reference standard performed on fresh-frozen tissue samples following surgery.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov